



**SPENCER DAYMAN MENINGITIS UK
(Working name Meningitis UK)**

REPORT AND FINANCIAL STATEMENTS

MARCH 31, 2011

REGISTERED CHARITY NUMBER 1076774

SPENCER DAYMAN MENINGITIS UK

Contents	Page
Reference and Administrative Information	3
Structure, Governance and Management	4
The Current Position	6
Research and Awareness	8
Significant Activities	15
Financial Review	19
Plans for the Future	20

SPENCER DAYMAN MENINGITIS UK

ALSO KNOWN AS MENINGITIS UK

TRUSTEES ANNUAL REPORT YEAR ENDED 31 March 2011

Name: Meningitis UK is the working name of Spencer Dayman Meningitis UK

Registered Charity No: 1076774

LEGAL AND ADMINISTRATIVE INFORMATION

Registered Office and Operational Address:

25 Cleeve Wood Road

Downend

Bristol

BS16 2SF

Tel: 0117 3737373

Fax: 0117 3737374

Email: information@meningitisUK.org

Website: www.meningitisUK.org

Trustees

Richard Gillett – Chairman

Sarah Portway-Berry – Deputy Chair

Nichola Sheppard

Christopher Northover

Matthew Torrible

Patrons

Denis Law, Robert Woodward, Jane Seymour, James Keach, Joe Swash, Sarah Ayton MBE, Robin Cousins MBE, Shirley Webb and Ken Loach.

Chief Executive

Steve Dayman MBE

Scientific Medical Advisory Panel 2010/2011

Professor Dlawer Ala'Aldeen Retired 1/8/10

Professor Peter Beverley Retired 1/8/10

Dr Ray Borrow

Dr Jeremy Brown

Dr Myron Christodoulides

Professor Ian Feavers

Professor Adam Finn Retired 1/1/11

Professor Catherine Ison Retired 1/4/10

Dr Paul Langford - Chairman

Professor Robert Read

Simon Nadel Appointed 1/1/11

James Stuart Appointed 1/1/11

**SPENCER DAYMAN MENINGITIS UK
ALSO KNOWN AS MENINGITIS UK**

LEGAL AND ADMINISTRATIVE INFORMATION (continued)

Primary Bankers

- 1 Barclays Bank Plc, 86 Queens Road, Clifton, Bristol BS8 1RB
- 2 NatWest, Bristol City Office, PO Box 238, 32 Corn Street, Bristol BS99 7UG
- 3 Northern Bank, 6 High Street, Ballymoney, Co. Antrim BT53 6AD
- 4 Standard Life, 1 Conference Square, Edinburgh EH3 8RA
- 5 CAFCash Ltd, PO Box 289, West Malling, Kent ME19 4TA

Solicitors

Burroughs Day, 14 Charlotte Street, Bristol BS1 5PT
Gregg Latchams, 7 Queen Square, Bristol BS1 4JE

Auditors

Stone & Partners, 571 Fishponds Road, Fishponds, Bristol BS16 3AF

STRUCTURE, GOVERNANCE AND MANAGEMENT

Spencer Dayman Meningitis UK - working name Meningitis UK - is a registered charity (no. 1076774). The charity's governing document is its Trust Deed dated 13 May 1999 (Supplemental Revised Deed Dated Feb 2009). The charity is unincorporated and governed by a Board of Trustees. The number of trustees cannot be fewer than three or more than eight.

At the end of the year, the Board of Trustees consisted of five people, and met on a regular basis (six times during the year). The current Board of Trustees has a range of skills including banking, marketing/communications, insurance, bereavement and law. The trustees work closely with the senior management team.

A full strategic planning and budgeting process is undertaken with detailed budgets and plans presented to and approved by the trustees on an annual basis.

The Board of Trustees is mindful that the composition as a whole should include a range of skills in order to provide high-quality, effective governance.

New trustees are recruited and appointed by the Board of Trustees. Prospective trustees are interviewed by the Chairman, Deputy Chair and Chief Executive. New trustees are given an Induction Pack which includes information about governance and their responsibilities along with copies of board meeting minutes, the Strategic Business Plan and the charity's most recent annual report and accounts. Prospective trustees have to confirm in writing that they are eligible to serve. They are then invited to a Board Meeting as a prospective Trustee before the board appoints them. All trustees subscribe to a number of publications including the bi-monthly Governance journal and the NCVO Trustee & Governance newsletter plus regularly review guidance from the Charity Commission and attend relevant events. During the year under review, the current Board of Trustees advertised for new trustees through an open recruitment process. Three new trustees, with skills to complement existing board members, were invited to join the board, with a proposed start date in 2011/2012.

**SPENCER DAYMAN MENINGITIS UK
ALSO KNOWN AS MENINGITIS UK**

Organisational Structure (continued)

Trustees are not remunerated but are recompensed for reasonable out of pocket expenses associated with fulfilling their responsibilities.

Objectives of the Charity for the Public Benefit

The aim of the charity is to develop vaccines to eradicate all forms of meningitis and, in the absence of vaccines to protect against all form of the disease, to raise awareness of the importance of recognising the symptoms of the disease,.

The principal objects of the charity are:

- (1) To encourage, support and provide financial grants to established meningitis research centres in the UK for research into developing vaccines to eradicate all strains of meningitis and associated infection and diseases whether bacterial or viral in nature.
- (2) To advance the education of the public and raise awareness of the signs and symptoms of meningitis and associated infections and diseases through the promotion, publication and support of such research.

Since the charity's inception in 1999, Meningitis UK has made a significant contribution towards combating meningitis. However, there is still no vaccine to protect against all forms of the disease in the UK and meningitis remains a serious health threat to the UK population, causing a significant burden in terms of both death and disability.

The beneficiaries of the work of the charity are the general public and as such the trustees, having referred to the Charity Commission's guidance on public benefit, are satisfied that the charity's activities contribute to the benefit of the public.

Object (1) – Preventative research: The charity invites research centres throughout the UK to apply for a grant to aid existing or new research that will contribute towards eradicating meningitis and associated diseases in the UK. Developing a successful vaccine against meningitis could potentially save more than 300 lives a year and also relieve the burden of hospital treatment and people who are left needing life-long care due to the after effects of meningitis. Meningitis can strike any person of any age or ethnic origin; however children, young adults and older people are most at risk. All knowledge acquired as a result of the research is made widely available to further the charity's aim to eradicate all forms of meningitis and to advance the global understanding of the disease.

Object (2) – Awareness Programme: The charity runs a nationwide public awareness programme to alert people to the common symptoms of meningitis and the need to act quickly. Prompt treatment can mean the difference between life and death, and increase the chance of a successful outcome. The charity's symptoms information and educational campaigns are therefore instrumental in saving lives and preventing disability.

SPENCER DAYMAN MENINGITIS UK ALSO KNOWN AS MENINGITIS UK

Organisational Structure

Meningitis UK is a national charity covering the whole of the UK with headquarters in Bristol. It is governed by a Board of Trustees. The Chief Executive is responsible for the day-to-day management of the charity and leads a team of 11 full time and four part-time members of staff. Temporary staff are used when necessary to ensure the smooth-running of the charity. The Head Office is owned as a freehold property and is mortgaged to the National Westminster Bank in the names of the Property Trustees on behalf of Spencer Dayman Meningitis UK.

Meningitis UK benefits from the work of a large number of volunteers who both fundraise on our behalf and provide support to our administrative work at our office in Bristol. All volunteers are given an induction and full support.

Trustees and staff work to a three year Strategic Business Plan. This is reviewed annually. Annual operational plans and budgets are then produced and approved by the Board of Trustees. The charity's financial performance is monitored on a monthly basis by the senior management team and quarterly reports are provided to the Board of Trustees.

Meningitis UK's past and future success is dependent on many people. The dedication of our donors and supporters is critical to our ongoing success. Our volunteers generously give up their precious time. Our Scientific Medical Advisory Panel (SMAP) contribute their expertise and knowledge to help us make best use of our research grant programme, our Patrons lend their names and their support to our work and our small, but dedicated and hardworking, team of staff ensure that we deliver our programmes and activities to our best possible ability. The trustees extend our appreciation to each and every one of them.

Risk Management

The trustees recognise that risk management is an essential part of operational planning. During the year, the Board of Trustees initiated a programme to review and assess the risks facing the charity led by one of the trustees with risk management experience. Financial risks are minimised through a number of accounting and operational procedures, in addition to systems for budgetary planning and monitoring. Where appropriate, risks are covered by insurance.

SPENCER DAYMAN MENINGITIS UK ALSO KNOWN AS MENINGITIS UK

The Current Position

Incidence of Meningitis

In 2010, it is estimated that there were in the region of 3,000 cases of all forms of bacterial meningitis and associated diseases in the UK.

Meningitis and its associated diseases can affect anyone of any age. The disease occurs most frequently in young children and continues to be a major infection causing death in the under fives, young adults aged between 15-24 years old, and the elderly. Cases occur throughout the year, with a marked increase in the winter months.

Meningitis is caused when the protective membrane covering the brain and spinal cord - known as the meninges - becomes inflamed, usually as a result of an infection. This infection is usually caused by viruses or bacteria. It is very rare for viral meningitis to be life threatening. However, bacterial meningitis is extremely dangerous and strikes with incredible speed. The bacteria can cause two distinct forms of the disease - meningitis (infection of the meninges that surround the brain) and septicaemia (blood poisoning).

One in ten patients die and of those who do survive, one in seven are left with disabilities such as deafness or partial paralysis. In some cases, damage to tissues is so severe that patients must undergo limb amputation or are left with permanent brain damage.

SPENCER DAYMAN MENINGITIS UK ALSO KNOWN AS MENINGITIS UK

Vaccine Development Progress

Great advances have been made in meningitis vaccine development over the last 20 years. Vaccines now exist in the UK routine immunisation programme to protect against pneumococcal meningitis, *Haemophilus influenzae type b* (Hib) and Meningitis C. These vaccines are making significant contributions in reducing mortality and morbidity of these forms of the disease.

Although significant progress has been made, it is important to remember that there is still no vaccine to protect against all forms of the disease, including the most common form in the UK, meningococcal group B (Meningitis B), and streptococcal group B, the most common cause of severe infection in newborn babies in the UK. The research community is working hard to address this gap.

In April, a new vaccine covering more strains of pneumococcal disease was introduced into the Childhood Immunisation Programme in the UK. The new Prevenar 13 vaccine protects against 13 types of pneumococcal bacteria compared to the previous vaccine which covered just seven. The new vaccine follows exactly the same three dose schedule as the previous vaccination at two, four and 13 months. Pneumococcal meningitis is the second most common form of bacterial meningitis in the UK. Although pneumococcal meningitis is less common than meningococcal meningitis, it is a lot more life-threatening; one in six children will die and half of those who survive will be left with severe disabilities such as deafness, brain damage and seizures. There are 92 strains of pneumococcal bacteria. Although this is a great step forward, there is still important work to do in this area.

A new vaccine called Menveo received European approval during the period and was made available to people in the UK travelling to other countries. The new vaccine is a conjugate vaccine which protects against four of the five major groups responsible for causing meningococcal meningitis - A, C, W135 and Y. UK travellers can now protect themselves while visiting countries where these strains pose a serious risk, such as certain parts of Africa, South America and those going on a pilgrimage to the Hajj.

During the period under review, pharmaceutical company Novartis released data supporting their potential new vaccine against Meningitis B. These data show that the vaccine has the potential to offer protection against 70 per cent of 1,000 strains collected from across Europe and to work safely alongside other vaccines. The trustees are hopeful that this vaccine will pass all safety and effectiveness measures, so that it can be licensed in the EU and could then be included into the UK's childhood immunisation programme. If the vaccine is successfully introduced, monitoring and surveillance will be of paramount importance. It is also important to note that this is a first generation vaccine so it is vital that research continues.

SPENCER DAYMAN MENINGITIS UK ALSO KNOWN AS MENINGITIS UK

RESEARCH AND AWARENESS FOR PUBLIC BENEFIT

Meningitis UK's Research

Because of how quickly the disease can strike and the fact that many of its symptoms are so similar to the common cold and flu, meningitis can be very difficult to detect. Many patients show the more specific symptoms - such as a pin prick rash, stiff neck and aversion to bright light - too late or not at all, which makes the disease very difficult to diagnose. For these reasons, Meningitis UK believes that the only way to eradicate the disease is through prevention. Developing preventative vaccines to protect against all forms of meningitis and associated diseases is Meningitis UK's sole focus.

Meningitis UK is the only charity solely dedicated to funding meningitis vaccine development research in the UK. The charity awards grants to scientists and doctors based in Universities, hospitals and other research institutions in the UK in areas related to prevention of meningitis, particularly vaccine development.

Meningitis UK is a member of the Association of Medical Research Charities (AMRC) - the leading umbrella organisation representing medical research charities. The organisation provides guidance and shares best practice. All of AMRC's member charities are required to have a clearly defined research strategy and demonstrate good peer review when awarding research grants.

The charity normally holds a research grant round on an annual basis. Applications for funding are reviewed by Meningitis UK's Scientific Medical Advisory Panel made up of scientists who are leading experts in the field of meningitis. The panel scrutinise project proposals to ensure that the charity's funds are used to fund top-quality, cutting-edge research.

Meningitis UK operates a rigorous peer review process. All lead investigators must apply using grant application forms. Guidance notes and terms and conditions are also provided. Investigators are given a three month period to complete and return their application. Collaboration between research groups is actively encouraged.

Once all the applications are received, the Chairman of our Scientific Medical Advisory Panel will identify panel members who are experts in the particular area of research pertaining to the proposed projects.

The panel member will then identify a minimum of two internationally renowned scientists with a particular knowledge of the area of research proposed to act as external referees. These referees will then give their opinion regarding the scientific merit of the proposed study.

A Scientific Medical Advisory Panel meeting is then arranged where all recommended research grant applications are considered and scientific merit permitting, grant awards are recommended to the charity's Board of Trustees for final approval.

**SPENCER DAYMAN MENINGITIS UK
ALSO KNOWN AS MENINGITIS UK**

RESEARCH AND AWARENESS FOR PUBLIC BENEFIT (continued)

Scientific Medical Advisory Panel

Four members retired from the board at the end of the year and two new members were recruited. Others are due to take up posts during the coming year 2011-2012 (see page 3 for composition of panel members).

Ongoing Research Studies

The following research studies took place during the period:

Dr Christine Rollier, University of Oxford.

Development of a novel multivalent Group B meningococcal vaccine based on adenovirus vectors.
Grant Award £149,952. September 2010 – September 2012

Dr Nigel Saunders, University of Oxford.

Microserological determination of N. lactamica induced cross-protective meningococcal immunity.
Grant Award £156,512. January 2008 – November 2011

Professor John Heckels, University of Southampton.

Identification of meningococcal antigens associated with development of cross-reactive immunity.
Grant Award £176,859. January 2008 – October 2011

Professor Robert Heyderman, University of Bristol

Mechanisms of mucosal immunity to systemic immunisation with a meningococcal serogroup B outer membrane vesicle vaccine.

Grant Award £260,000. January 2007 – October 2011

Professor Andrew Pollard, University of Oxford

An Opa protein vaccine against serogroup B meningococcal disease: from proof in principle to phase I clinical trials.

Grant Award £105,941. September 2007 – July 2011

SPENCER DAYMAN MENINGITIS UK ALSO KNOWN AS MENINGITIS UK

RESEARCH AND AWARENESS FOR PUBLIC BENEFIT (continued)

New Projects

Two projects were awarded funding in March 2011:

Professor Andrew Gorringe and Professor Robert Read, HPA (Porton Down) and University of Sheffield respectively.

Competitive carriage of Neisseria spp.: discovering new methods of inhibiting carriage of Neisseria meningitidis.

Grant Award £133,830. September 2011 – September 2012

Professor Simon Kroll, Imperial College London

Septicaemia and meningitis in premature neonates: defining the role of the developing intestinal microbiota.

Grant Award £149,075. September 2011 – February 2014

At the end of the period, the total value of the charity's current research portfolio of preventative studies in the UK stands at circa £1.2 million.

Completed Research Projects

The following research studies were completed during the period:

Professor Robert Read, University of Sheffield

Human immune response to experimental colonisation with Neisseria lactamica.

Grant Award £205,062. October 2006 - July 2010

Dr Karl Wooldridge, University of Nottingham

Vaccine potential of meningococcal secreted proteins

Grant Award £148,726. May 2008 – December 2010

Research Output

A number of peer-reviewed papers were published and oral presentations given by Meningitis UK researchers. Examples include:

- Evans et al (2010) Nasopharyngeal colonisation by *Neisseria lactamica* and induction of protective immunity against *Neisseria meningitidis*. Clinical Infectious Diseases
- Immunoproteomics has revealed potential candidates for inclusion in multi-component serogroup B meningococcal vaccines. Poster presentation by JN Williams at 17th International Pathogenic *Neisseria* Conference, Banff, Canada September 2010
- Immunoproteomics and pan-meningococcal antigen discovery. Oral presentation by Professor Heckels at 17th International Pathogenic *Neisseria* Conference, Banff, Canada September 2010

SPENCER DAYMAN MENINGITIS UK ALSO KNOWN AS MENINGITIS UK

RESEARCH AND AWARENESS FOR PUBLIC BENEFIT (continued)

- Investigation of potential vaccine candidates for the prevention of serogroup B meningococcal infection. Poster presentation by Dr. Phillips at University of Southampton Postdoctoral Conference, December 2010
- British Society for Immunology Annual International Congress, Liverpool December 2010
- Meningitis UK Friends' Day

Further papers are in the process of being written up or have been submitted for publication.

National Awareness Programme

Because of the speed by which meningitis strikes and the fact that its symptoms are so similar to the common cold and flu, the charity's ultimate goal is to eradicate the disease completely through the development of preventative vaccines. However, in the absence of such vaccines, the charity continues to run a nationwide public awareness campaign to alert people to the common symptoms of meningitis and the need to act quickly, which can mean the difference between life and death.

Materials are offered free of charge to the public and to locations such as doctors' surgeries, pharmacies and work places. Meningitis UK runs regular awareness campaigns to alert people to the dangers of meningitis and to target high-risk groups such as schools, nurseries and universities.

Awareness materials include:

- Handy wallet-sized symptom cards
- 'What you need to know about Meningitis' leaflets
- 'Check the symptoms' fridge magnets
- Symptoms posters

Talks and presentations are also given to groups such as schools, nurseries and other bodies nationwide, plus the charity has an awareness trailer which visits locations across the country. The charity's website plays a vital role in encouraging people to become familiar with the symptoms of meningitis.

'Look out 4 Meningitis' Winter Awareness Campaign

Our 2010/11 winter awareness campaign, 'Look out 4 Meningitis' aimed to remind people to be alert to the symptoms during the winter months, when cases are at their highest. The campaign featured a specially-designed poster illustrating a line of people of different ages, to remind people that meningitis can affect anyone of any age. The campaign was launched in December by Meningitis UK Patron and acclaimed film director, Ken Loach, along with his granddaughter Holly who had pneumococcal meningitis as a baby.

SPENCER DAYMAN MENINGITIS UK ALSO KNOWN AS MENINGITIS UK

RESEARCH AND AWARENESS FOR PUBLIC BENEFIT (continued)

To get the message out as far as possible, Meningitis UK asked supporters to support the campaign by distributing copies of the poster and symptoms cards to GP surgeries, schools, nurseries or other establishments in their local area. Over 20 of the charity's supporters agreed to share their experiences with the media and the campaign proved a big success. Over 1300 posters and 30,000 symptom cards were distributed and the campaign received over 60 mentions in the press, putting meningitis in the minds of thousands of people.

World Meningitis Day

As a member of the Confederation of Meningitis Organisations (COMO), Meningitis UK coordinated several activities to promote World Meningitis Day on Sunday 24th April 2011. This resulted in a significant amount of coverage in the media and on social networking sites worldwide.

Website Redevelopment – Making Research Accessible

During the period, the charity reviewed the research section of its website to ascertain people's views of the content and how it could be made more accessible, appealing and user-friendly. This redevelopment was carried out with the help of a Masters student from the University of the West of England's Science Communication Unit. Data on user attitudes and needs was collected. As a result of feedback, a new section of the website was created combining information about research and meningitis in one easy to navigate section with a number of new features were developed, including:

- Interactive timeline depicting scientific advances
- Tabbed pages for research projects showing both scientific/lay summaries and videos
- Educational animation and game demonstrating how the immune system works and the challenges of developing a Meningitis B vaccine
- Two interactive graphs showing the impact of vaccines and treatment developments
- Research FAQ page
- Interactive medical glossary defining scientific terms across the whole site

SPENCER DAYMAN MENINGITIS UK ALSO KNOWN AS MENINGITIS UK

RESEARCH AND AWARENESS FOR PUBLIC BENEFIT (continued)

Website Redevelopment – Making Research Accessible (continued)

Excellent feedback was received post-implementation, with significant improvements on all ratings including navigation, understanding, information and engagement.

PneumoAware Campaign – Phase2

During the period, Meningitis UK continued to play a pivotal role in raising awareness of pneumococcal disease through the PneumoAware Campaign, as one of the five patient organisations in the working group. The objectives of the campaign are to:

- Increase awareness of pneumococcal disease
- Drive education about vaccines
- Improve pneumococcal vaccination uptake
- Engage with policy makers on pneumococcal disease and vaccination

The campaign is aimed at public health and political audiences in particular. In order to publicise the campaign, a report had been produced during the previous period to highlight the dangers of pneumococcal infection and to summarise the recommendations within each of the above areas to drive necessary change. Three versions of the report, sponsored by Pfizer, were produced for England, Scotland and Wales, containing country-specific information.

As part of phase 2, five regional launches were held in the South West (Bristol), North West (Manchester), South East (House of Commons, London), Scotland (Holyrood, Edinburgh) and Wales (Welsh Assembly, Cardiff Bay) to publicise the report and gain support.

PARTNERSHIPS WITH OTHER ORGANISATIONS

Meningitis UK is a member of the following organisations:

- Association of Medical Research Charities (AMRC)
- Confederation of Meningitis Organisations (COMO)
- Pneumococcal Awareness Council of Experts (PACE)
- National Council for Voluntary Organisations (NCVO)
- Fundraising Standards Board (FRSB)
- Institute of Fundraising (IoF)

Meningitis UK also has a working partnership with the Meningitis Trust. Meningitis UK refers families enquiring about emotional and financial help to the Meningitis Trust whose focus is to provide a range of aftercare services to people who have been affected by meningitis. In return the Meningitis Trust highlights our mission to those families who wish to support research to eradicate the disease.

**SPENCER DAYMAN MENINGITIS UK
ALSO KNOWN AS MENINGITIS UK**

PARTNERSHIPS WITH OTHER ORGANISATIONS (continued)

We also work closely with other health-related bodies such as the Department of Health, Health Protection Agency, Health Protection Scotland and Public Health Agency Northern Ireland.

SIGNIFICANT ACTIVITIES

Vaccine Awareness & Public Engagement

On 10 April 2010, we held our third national annual Friends' Day in Bristol. This has now become a popular event which our supporters look forward to. The day provided the opportunity for families to exchange their experiences with others who have suffered the devastation that meningitis can cause. Peer support is encouraged by Meningitis UK which helps families deal with the trauma they often suffer.

The day was sponsored by Novartis Vaccines, Pfizer and Glaxo Smith Kline. It was attended by over 100 supporters. The day was introduced by the charity's Chairman, Richard Gillett. Professor Paul Langford, Chairman of the charity's Scientific Medical Advisory Panel, gave an overview of the present position regarding the disease and vaccine development and supporters were updated about the charity's work. Workshops were run to discuss future work and seek people's opinions about future priorities and potential ideas. Therapeutic sessions were also available including art therapy and 'Coping with bereavement'.

Later in the day, a memorial service was held at the Memorial Woodlands near Bristol. Families were able to light a candle and read out a verse in memory of their loved one. Many friends then visited Meningitis UK's memorial garden which is part of the charity's Forever Fund programme.

Steve Dayman MBE

Steve Dayman Chief Executive was honoured in the Queen's 2011 New Year's Honours list for services to healthcare. The trustees wish to record their gratitude to Steve Dayman who, for more than a quarter of a century has been at 'the coalface' leading, inspiring, often comforting the grieving and has been instrumental in raising millions of pounds throughout the country to fund research and awareness campaigns, ensuring that meningitis remains a disease of national importance. This honour significantly raised the profile of Meningitis UK and the disease in general.

SPENCER DAYMAN MENINGITIS UK ALSO KNOWN AS MENINGITIS UK

FUNDRAISING

Friends and Supporters

The charity wishes to thank all our friends and supporters who have been actively involved with our fundraising efforts - their commitment is truly appreciated. Over the 2010/2011 period, the total amount raised from friends and supporters was £487,201.

They include Terry and Sue Laing in memory of Helen, Ian and Sue Hession in memory of Andrew, Karen Steve and Karen Pegler in memory of Chris Pegler, Sarah and Tyrone Johnson in memory of Ryan, Fidel and Abby Lema-Dalton in memory of Eloise, the Bromovsky family in memory of Francis, Andy Usher who ran for Lydia Cross, John and Lesley Tanton in memory of Mark, Andy and Georgina Keeling plus Mark Whitehead in memory of Liam, Clare and Stefan Fox in memory of Clara, Shaun and Rachel Ogden in memory of their son Thomas, James & Sue Virgo and Rose Hardwick in memory of Sam, Simon Funnell and Lucie Dunbar in memory of Ella, Sam Vincent in memory of Ben, Quentin and Surj Stott in memory of Dylan, Andrew Wood and Liesa Hind in memory of Elliott plus Charles and Mary Dobson.

Other individuals who gave their time and energy include Bob Birdsall, Steve Fear, Steve Keeping, Dave Cox, Alan Skidmore, Judith Reed, Phil Cook and Carl Monteith.

The charity is grateful to John and Michelle Bresnahan who lost their 16 year-old son, Ryan on 31 March 2010. Ryan was taken by meningococcal meningitis and septicaemia within hours of showing the signs of illness. Together with their daughter, Charlotte, John and Michelle immediately set up the 'Ryan Bresnahan – Life for a Cure' fund to support Meningitis UK's Search 4 a Vaccine Campaign in memory of Ryan. At 31 March 2011, £105,964 had been raised through donations and various fundraising events. These funds have been applied to support the charity's new research project to be undertaken by Professor Read at the University of Sheffield.

SPENCER DAYMAN MENINGITIS UK ALSO KNOWN AS MENINGITIS UK

FUNDRAISING (Continued)

Events

The charity's supporters took part in a wide variety of fundraising events in 2010/2011; these included:

- Londonderry to Rostrevor walk in May raised £42,100 covering 201 miles over 9 days. The Bridlington to Brighton walk in October raised £42,700 covering 330 miles over 16 days. The latter was Steve Dayman's thirtieth marathon walk for the cause. Over 36,000 symptoms cards were distributed during the two marathon walks.
- The charity's annual 13-mile Summer Stroll from Bath to Bristol, now in its fifth year, raised over £20,000 with more than 160 supporters taking part.
- The Bath Half Marathon, Virgin London Marathon, Great North Run, Edinburgh Marathon, Bristol Half Marathon, London 10,000 and other independent runs.
- A range of charity challenges including charity treks, cycle rides, abseils and skydives. These were very popular, raising a total of £62,000. Notable events include a charity hike up Snowdon by Steve Martin and Mark Burrell in memory of Ruby which raised £5,130, the Dagenham Motors charity cycle ride organised by Malcolm Tutton which raised £4,093 and Meningitis UK's Avon Gorge Abseil which raised over £3,000.
- The inaugural annual Christmas Draw, held between November and December, performed well, raising £14,000 in its first year with supporters selling thousands of tickets to friends and family.
- The annual capital mega-raid, London Fourtunes raised over £19,000, attracting two of the most competitive student RAGs, Loughborough and Nottingham, as well as Surrey, Cambridge and Strathclyde. Other student street collections were held in cities all over the country, including Exeter, Loughborough, Liverpool, Brighton, Birmingham and Swansea.
- The Big Bug Hunt, Meningitis UK's national nursery-led event, was held between March and May 2010. 117 nurseries took part, raising over £7,500. This also helped to raise awareness within this high-risk age group. Materials highlighting the symptoms of the disease in the under-fives were given to the nurseries and thousands of symptoms cards were distributed to parents.
- Various fundraising activities were organised by schools including dress down days, charity balls, discos, raffles and merchandise sales. In Gloucestershire, Katherine Lady Berkeley School held various fundraising events throughout the year in memory of 18 year-old Chris Pegler, a former pupil, helping to raise £2,568 in February.

SPENCER DAYMAN MENINGITIS UK ALSO KNOWN AS MENINGITIS UK

FUNDRAISING (Continued)

Trusts and Corporations

Significant grants from charitable trusts which have supported the charity include: the Charles Wolfson Charitable Trust, Philip King Charitable Trust, Herbert and Peter Blagrove Charitable Trust, Starfish Trust, Souter Charitable Trust, Emerton Christie Charity and Lewis Family Charitable Trust.

In July, Hertfordshire printing company, Alpine Press pledged to print all Meningitis UK's printed resources free of charge, resulting in an annual saving in the region of £15,000. This kind gesture came after Assistant Production Manager, Zoltan Loczy lost his daughter Milly to the disease in May aged just four-and-a-half years. We wish to thank Mr Maurice Grainger, Managing Director for his wonderful support.

Other major corporate supporters include: Novartis Vaccines UK Ltd, NSG Group, Burroughs Day Solicitors, Yorkon Ltd, Pfizer, Federation of Master Builders – Bristol Branch, Royal London Group, Simply Health (Bristol), Barclays Retail Financial Services, Bristol Car & Van Hire and Stone & Partners.

FINANCIAL REVIEW

With no statutory funding, Meningitis UK relies entirely on charitable contributions to continue its vital work. The trustees are pleased to report that fundraising held up strongly during these financially difficult times.

The income for the charity in 2010-2011 was £1,227,778, a 43% increase on the previous year.

Growth occurred principally in voluntary income, which reached £872,059 (£554,723 in 2010). The principle income streams were friends and supporters, events organised by the charity and grant-giving institutions and companies. Schools and universities raised £73,165 from collections and events. The charity received no legacy income.

The charity's charitable expenditure amounted to £463,230. Costs relating to fundraising and a small amount of merchandising were £263,071 which equates to 21% of income generated. Governance costs were £47,963. Total expenditure was £774,264.

Statement of Reserves

The trustees regularly review the level of reserves. The trustees have considered the amount of reserves held at 31 March 2011, and have decided to hold £200,000 in reserve for 2011/12 (see note 13 of the accounts). This equates to approximately three months' running costs.

SPENCER DAYMAN MENINGITIS UK ALSO KNOWN AS MENINGITIS UK

Investment Performance

The charity does not have any committed long term income. Investments are maintained in a readily realisable form and the performance of the investments is reviewed regularly by the Trustees. The Trustees have the power to deposit or invest in any lawful manner. The Trustees' policy is to hold its investment income, not immediately required, in short term deposits not exceeding 12 months.

PLANS FOR THE FUTURE

The charity's research strategy is reviewed on a regular basis. The Scientific Medical Advisory Panel makes recommendations on the charity's research strategy based on the changing areas of need.

The trustees plan to increase the charity's research portfolio focusing on preventative studies. The next grant round process will commence in the summer of 2011. Scientific merit permitting, new research grants will be approved by December 2011. The charity will invite applications focusing on preventative studies into eradicating all forms of meningitis and associated diseases including meningococcal, pneumococcal and streptococcal. Collaboration between research groups will continue to be encouraged.

Given the fact that meningitis continues to wreak havoc on people's lives, it is vitally important that the charity's research to eradicate all forms of the disease continues. In the absence of vaccines to protect against all forms of the disease, we will continue to improve the public's knowledge of meningitis, encouraging early diagnosis and prompt treatment, in collaboration with other charities, agencies and health professionals.

The trustees are mindful that the present economic climate remains unpredictable. Nevertheless, they are determined to continue with the established fundraising initiatives in order to support the charity's existing and proposed research programmes.

**SPENCER DAYMAN MENINGITIS UK
ALSO KNOWN AS MENINGITIS UK**

Responsibilities of the Trustees

The trustees are responsible for the preparation of accounts for each financial year, which give a true and fair view of the charity's financial activities during the year and of its financial position at the end of the year. In preparing the accounts the trustees are required to: -

- Select suitable accounting policies and then apply them consistently.
- Make judgements and estimates that are reasonable and prudent.
- State whether applicable accounting standards and statements of recommended practice have been followed, subject to any departures disclosed and explained in the account.
- Prepare the accounts on a going concern basis unless it is inappropriate to presume that the charity will continue business.

The trustees are responsible for keeping proper accounting records which disclose with reasonable accuracy at any time the financial position of the charity and to enable them to ensure that the accounts comply with the Charities Act 1993. They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Signed on behalf of the Trustees



29th September 2011

INDEPENDENT AUDITORS' REPORT

TO THE TRUSTEES OF SPENCER DAYMAN MENINGITIS UK

We have audited the financial statements of Spencer Dayman Meningitis UK for the year ended March 31, 2011 which comprise the Statement of Financial Activities, the Summary Income and Expenditure Account, the Balance Sheet and related notes. The financial statements have been prepared under the accounting policies set out therein.

This report is made solely to the charity's trustees, as a body, in accordance with Sections 43 of the Charity's Act 1993 and the regulations made under section 44 of that Act. Our audit work has been undertaken so that we might state to the charity's trustees those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charity and the charity's trustees as a body, for our audit work, for this report, or for the opinions we have formed.

Respective responsibilities of trustees and auditors.

The trustees' responsibilities for preparing the Annual Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice) are set out in the Statement of Trustees' Responsibilities.

We have been appointed as auditors under section 43 of the Charities Act 1993 and report in accordance with regulations made under that Act. Our responsibility is to audit the financial statements in accordance with relevant legal and regulatory requirements and International Standards on Auditing (UK and Ireland).

We report to you our opinion as to whether the financial statements give a true and fair view and are prepared in accordance with the Charities Act 1993. We also report to you if, in our opinion the information given in the Trustees' Annual report is not consistent with those financial statements, the charity has not kept sufficient accounting records, if the charity's financial statements are not in agreement with these accounting records or if we have not received all the information and explanations we require for our audit.

Basis of audit opinion

We conducted our audit in accordance with International Standards on Auditing (UK and Ireland) issued by the Auditing Practices Board. An audit includes examination, on a test basis, of evidence relevant to the amounts and disclosures in the financial statements. It also includes an assessment of the significant estimates and judgements made by the trustees in the preparation of the financial statements, and of whether the accounting policies are appropriate to the charity's circumstances, consistently applied and adequately disclosed.

**INDEPENDENT AUDITOR'S REPORT
TO THE MEMBERS OF SPENCER DAYMAN MENINGITIS UK**

continued


We planned and performed our audit so as to obtain all the information and explanations which we considered necessary in order to provide us with sufficient evidence to give reasonable assurance that the financial statements are free from material misstatement, whether caused by fraud or other irregularity or error. In forming our opinion we also evaluated the overall adequacy of the presentation of information in the financial statements.

Opinion

In our opinion the financial statements:-

- give a true and fair view, in accordance with United Kingdom Generally Accepted Accounting Practice, of the state of the charity's affairs as at March 31, 2011 and of its incoming resources and application of resources, for the year then ended and
- have been prepared in accordance with the Charities Act 1993.

Name of firm:
STONE & PARTNERS

A handwritten signature in black ink that reads "Stone - Stone & Partners". The signature is written in a cursive, flowing style.

Statutory Auditor
STONE & PARTNERS
571 FISHPONDS ROAD
FISHPONDS
BRISTOL
BS16 3AF

September 29, 2011

SPENCER DAYMAN MENINGITIS UK

STATEMENT OF FINANCIAL ACTIVITIES

MARCH 31, 2011

	Notes	Restricted funds £	Unrestricted funds £	Total 2011 £	Total 2010 £
Incoming resources					
Incoming resources from generated funds:-					
Voluntary income	2	349,421	522,638	872,059	554,723
Activities for generating funds:					
Fundraising events	3	-	342,689	342,689	286,828
Sale of merchandise		-	10,061	10,061	5,741
Investments income: bank deposit interest	4	-	2,969	2,969	2,567
Other income		-	-	-	6,886
Total incoming resources		<u>349,421</u>	<u>878,357</u>	<u>1,227,778</u>	<u>856,745</u>
Resources expended					
Costs of generating funds					
Costs of generating voluntary income	5	1,824	174,216	176,040	149,744
Fundraising events	5	889	81,480	82,369	76,083
Fundraising trading:					
Cost of merchandise	5	10	4,652	4,662	3,967
Charitable activities	5	85,371	377,859	463,230	579,444
Governance costs	5	-	47,963	47,963	41,188
Total resources expended		<u>88,094</u>	<u>686,170</u>	<u>774,264</u>	<u>850,426</u>
Net incoming/(outgoing) resources		261,327	192,187	453,514	6,319
Transfers between funds		(8,838)	8,838	-	-
Reconciliation of funds					
Funds brought forward		<u>5,701</u>	<u>424,421</u>	<u>430,122</u>	<u>423,803</u>
Total funds carried forward		<u>258,190</u>	<u>625,446</u>	<u>883,636</u>	<u>430,122</u>

The statement of financial activities includes all gains and losses recognised in the year.
All incoming resources and resources expended derive from continuing operations

SPENCER DAYMAN MENINGITIS UK

BALANCE SHEET

AT MARCH 31, 2011

	Notes	2011 £	2010 £
Tangible fixed assets	6	202,364	188,677
Current assets			
Cash at bank		791,750	431,859
Debtors and prepayments	7	<u>31,066</u>	<u>33,942</u>
		822,816	465,801
Creditors: amounts falling due within one year	8	<u>37,579</u>	<u>124,860</u>
Net current assets		<u>785,237</u>	<u>340,941</u>
Total assets less current liabilities		987,601	529,618
Creditors: amounts falling due after one year	9	<u>103,965</u>	<u>99,496</u>
		<u>883,636</u>	<u>430,122</u>
Total Charitable Funds			
Restricted funds	12	258,190	5,701
Unrestricted funds	13	<u>625,446</u>	<u>424,421</u>
		<u>883,636</u>	<u>430,122</u>

The accounts were approved by the Trustees on
by the Chairman

and were signed on their behalf

.....
Richard Gillett

SPENCER DAYMAN MENINGITIS UK

NOTES TO THE FINANCIAL STATEMENTS

AT MARCH 31, 2011

1. Accounting policies Accounting convention

The accounts are prepared under the historical cost convention and in accordance with applicable accounting standards. In preparing the accounts the charity follows best practice as set out in the Statement of Recommended Practice Accounting and Reporting by Charities issued in March 2005.

Funds accounting

Funds held by the charity are:-

Restricted funds – These are funds that can only be used for particular restricted purposes within the objects of the charity. Restrictions arise when specified by the donor or when funds are raised for particular restricted purposes.

Unrestricted funds – These are funds which can be used in accordance with the charitable objects at the discretion of the trustees.

Designated funds – These are funds set aside by the trustees out of unrestricted general funds for specific future purposes or projects.

Incoming resources

All incoming resources are included in the statement of financial activities when the charity is entitled to the income and the amount can be quantified with reasonable accuracy.

Investment Income

Interest arising on cash deposits representing restricted donations is allocated to the specific research projects.

Resources expended

Expenditure is recognised on an accruals basis as a liability is incurred, and is reported as part of the expenditure to which it relates.

Costs of generating funds comprise the costs associated with attracting voluntary income and the costs of trading for fundraising purposes including the sale of merchandise.

Charitable expenditure comprises those costs incurred by the charity in the delivery of its activities. It includes both costs that can be allocated directly to such activities and those costs of an indirect nature necessary to support them.

Governance costs include those costs associated with meeting the constitutional and statutory requirements of the charity and include the audit fees and costs linked to the strategic management of the charity.

All costs are allocated between the expenditure categories of the Statement of Financial Activities on a basis designed to reflect the use of the resource. Costs relating to a particular activity are allocated directly, others are apportioned on an appropriate basis.

SPENCER DAYMAN MENINGITIS UK

NOTES TO THE FINANCIAL STATEMENTS

AT MARCH 31, 2011

Accounting policies continued

1. Continued Depreciation

Depreciation is provided on all tangible fixed assets with the exception of freehold property, in the year of acquisition, in equal instalments at rates calculated to write off fixed assets over their useful lives, as follows:

Office equipment	25% per annum straight line
Motor vehicles	25% per annum reducing balance
Freehold buildings & improvements	2% per annum straight line

2. Voluntary income

	Restricted £	Unrestricted £	Total 2011 £	Total 2010 £
Donations:				
Charitable Trusts	174,314	8,395	182,709	149,180
Corporate	63,475	64,409	127,884	48,073
Local Authority	-	1,100	1,100	250
Friends, supporters and general	111,632	375,569	487,201	304,179
Legacies	-	-	-	6,698
Schools and universities	-	73,165	73,165	46,343
	<u>349,421</u>	<u>522,638</u>	<u>872,059</u>	<u>554,723</u>

Voluntary income from friends, supporters and general donations includes £105,964 from the Ryan Bresnahan's Meningitis Appeal – 'a Life for a Cure' which is committed to raising funds in support of finding the ultimate vaccine, following the death of Ryan in March 2010. The trustees and the Bresnahan family have agreed the funds raised by the appeal are to be used to support a specific future project and are therefore to be treated as restricted income.

3. Fundraising events

	2011 £	2010 £
Organised events	333,541	276,551
School appeals	8,347	1,148
Media appeals	<u>801</u>	<u>9,129</u>
	<u>342,689</u>	<u>286,828</u>

4. Investment income

	2011 £	2010 £
Interest on cash deposits:		
Restricted funds	-	22
Unrestricted funds	<u>2,969</u>	<u>2,545</u>
	<u>2,969</u>	<u>2,567</u>

SPENCER DAYMAN MENINGITIS UK

NOTES TO THE ACCOUNTS

AT MARCH 31, 2011

(continued)

5. Total resources expended

	Allocation	Costs of generating funds				Charitable activities					Governance	Total 2011	Total 2010	
		Fundraising		Merchandise		Research grants		Research support		Education				
		Restricted	Unrestricted	Restricted	Unrestricted	Restricted	Unrestricted	Restricted	Unrestricted	Restricted				Unrestricted
		£	£	£	£	£	£	£	£	£				£
Costs directly allocated to activities:														
Grants	Direct					81,312	71,030						152,342	313,940
Research support costs	Direct							10	4,976				4,986	2,825
Fund raising and events	Direct	889	81,480						78	524	24,279		107,251	102,452
Cost of merchandise	Direct			10	4,652								4,662	3,967
Educational costs	Direct	370	13,110						4,991	2,072	45,726	6	66,274	72,983
Support costs allocated to activities:														
Staff costs (including training and recruitment)	Usage	1,447	136,875						39,159	1,447	144,448	35,164	358,538	282,823
Premises	Usage		1,848						3,389		924		6,161	7,703
Vehicle costs	Usage		3,722								3,722		7,444	8,601
Office costs	Usage	7	17,047						24,749	7	6,622	6,545	54,978	46,877
Legal and professional	Usage											6,248	6,248	3,984
Finance charges	Usage		1,614						2,959		807		5,380	4,271
		2,713	255,696	10	4,652	81,312	71,030	10	80,301	4,049	226,528	47,963	774,264	850,426

SPENCER DAYMAN MENINGITIS UK

NOTES TO THE FINANCIAL STATEMENTS

AT MARCH 31, 2011
(continued)

6. Tangible fixed assets	Property improvements	Freehold property	Motor vehicles	Office equipment	Total
	£	£	£	£	£
Cost					
At April 1, 2010	75,896	106,500	30,260	36,319	248,975
Additions	-	-	35,895	4,982	40,877
Disposals	-	-	(30,260)	-	(30,260)
	<u>75,896</u>	<u>106,500</u>	<u>35,895</u>	<u>41,301</u>	<u>259,592</u>
Depreciation					
At April 1, 2010	6,429	14,350	11,820	27,699	60,298
Charge for the period	1,518	2,050	4,610	5,182	13,360
Disposals	-	-	(16,430)	-	-
	<u>7,947</u>	<u>16,400</u>	<u>-</u>	<u>32,881</u>	<u>57,228</u>
Net book value					
March 31, 2011	<u>67,949</u>	<u>90,100</u>	<u>35,895</u>	<u>8,420</u>	<u>202,364</u>
Net book value					
March 31, 2010	<u>69,467</u>	<u>92,150</u>	<u>18,440</u>	<u>8,620</u>	<u>188,677</u>

The net book value of motor vehicles of £35,895 (£18,440 2010) includes an amount of £35,895 (£18,440 2010) in respect of assets held under hire purchase agreements.

7. Debtors	2011	2010
	£	£
Gift Aid	-	3,762
Prepayments	19,441	30,180
Sundry debtors	<u>11,625</u>	<u>-</u>
	<u>31,066</u>	<u>33,942</u>

SPENCER DAYMAN MENINGITIS UK

NOTES TO THE FINANCIAL STATEMENTS

AT MARCH 31, 2011
(continued)

8. Creditors: amounts falling due within one year	2011 £	2010 £
Trade creditors	14,593	21,204
Grants payable	-	73,100
Accruals	4,725	12,295
Obligations under hire purchase contracts	7,429	7,429
Bank loan	<u>10,832</u>	<u>10,832</u>
	<u>37,579</u>	<u>124,860</u>
9. Creditors: amounts falling due after one year	2011 £	2010 £
Bank loan	85,393	93,925
Obligations under hire purchase contracts	<u>18,572</u>	<u>5,571</u>
	<u>103,965</u>	<u>99,496</u>

The bank loan is for fifteen years with interest at 1.75% above base rate. It is secured by a legal mortgage dated July 31, 2006 on the freehold of the property.

10. Employees remuneration

Total remuneration for the period amounted to £324,987 (£256,430 – 2010)

No employee earned £40,000 per annum or more.

The average number of paid staff for the period was:

Full-time	11
Part-time	4

Total staff costs were as follows:

	2011 £	2010 £
Salaries and wages	296,772	235,225
Social security costs	28,215	21,205
Pension contributions	2,030	2,857
Training	4,867	2,259
Recruitment	4,921	3,368
Temporary staff	<u>21,733</u>	<u>17,909</u>
	<u>358,538</u>	<u>282,823</u>

SPENCER DAYMAN MENINGITIS UK

NOTES TO THE FINANCIAL STATEMENTS

AT MARCH 31, 2011
(continued)

11. Trustees' remuneration

Trustees were not remunerated and £Nil travel expenses were paid (2010 - £Nil).
A trustees' indemnity insurance policy premium was paid during the year

12. Restricted funds

	2011 £	2010 £
At April 1, 2010	5,701	71,030
Incoming resources	349,421	138,483
Resources expended	(88,094)	(203,812)
Transfers between funds	<u>(8,838)</u>	—
At March 31, 2011	<u>258,190</u>	<u>5,701</u>

13. Unrestricted funds

	2011 £	2010 £
At April 1, 2010		
Designated research projects	324,421	252,773
General fund	<u>100,000</u>	<u>100,000</u>
	<u>424,421</u>	<u>352,773</u>
Incoming resources	878,357	718,262
Transfers between funds	8,838	-
Resources expended	<u>686,170</u>	<u>646,614</u>
At March 31, 2011		
Designated research projects	330,047	324,421
Reserves fund	200,000	100,000
Future research projects fund	<u>95,399</u>	—
	<u>625,446</u>	<u>424,421</u>

SPENCER DAYMAN MENINGITIS UK

NOTES TO THE ACCOUNTS

AT MARCH 31, 2011

(continued)

14. Analysis of charitable funds

The movement of funds during the year was as follows:

Restricted funds	At April 1, 2010		Incoming Resources		Allocation of funds		Resources Expended		At March 31, 2011		Total
	Restricted funds	Unrestricted funds	Restricted funds	Unrestricted funds	Restricted funds	Unrestricted funds	Restricted funds	Unrestricted funds	Restricted funds	Unrestricted funds	
	£	£	£	£	£	£	£	£	£	£	£
Research projects											
University of Bristol (Prof Heyderman)		32,131	60,000			-20,131		12,000	60,000	0	60,000
University of Southampton (Prof Heckels)		59,232	15,557			-15,557			15,557	43,675	59,232
University of Nottingham (Dr Wooldridge)		74,363	88,079		-8,838	-74,363	79,241		0	0	79,241
Universty of Oxford (Dr Saunders)	4,064	100,502	900			-4,964	4,964	59,030	0	36,508	36,508
Universty of Oxford (Dr Rollier)			69,323						69,323	0	69,323
Ongoing research projects		58,193	105,890			191,671			105,890	249,864	355,754
	4,064	324,421	339,749	0	-8,838	76,656	84,205	71,030	250,770	330,047	580,817
Education/awareness projects											
Staff costs											
Sponsorship of promotional literature			2,475				2,475		0	0	2,475
Search engine optimisation campaign	1,637		5,197						6,834	0	6,834
Friends Open Day/Vaccine Forum									0	0	0
Online awareness programme			2,000				1,414		586	0	586
	5,701	324,421	349,421	0	-8,838	76,656	88,094	71,030	258,190	330,047	588,237

SPENCER DAYMAN MENINGITIS UK

NOTES TO THE FINANCIAL STATEMENTS

AT MARCH 31, 2011
(continued)

15. Grants payable

The grants payable during the year were as follows:

	2011 £	2010 £
University of Oxford (Dr Pollard)	-	52,969
University of Bristol (Prof Heyderman)	12,000	100,658
University of Southampton (Prof Heckels)	-	58,813
University of Oxford (Dr Saunders)	63,994	27,136
University of Nottingham (Dr Wooldridge)	74,363	74,363
University of Nottingham (Dr Woodridge equipment)	<u>1,985</u>	<u>-</u>
	<u>152,342</u>	<u>313,939</u>

16. Commitments

Commitments in respect of grants for approved projects which have not been accrued in the accounts

	2011 £	2010 £
Within one year	227,058	266,229
Between two and four years	<u>361,179</u>	<u>149,592</u>
	<u>588,237</u>	<u>415,821</u>
To be met from funds already raised:		
Restricted (note 12)	258,190	5,701
Designated (note 13)	330,047	324,421
To be met from funds to be raised	<u>-</u>	<u>85,699</u>
	<u>588,237</u>	<u>415,821</u>

SPENCER DAYMAN MENINGITIS UK

NOTES TO THE FINANCIAL STATEMENTS

AT MARCH 31, 2011
(continued)

17. Analysis of net assets between funds

	General Funds £	Designated Funds £	Restricted Funds £	Total £
Tangible fixed assets	202,364	-	-	202,364
Current assets	234,579	330,047	258,190	822,816
Current liabilities	(37,579)	-	-	(37,579)
Long term liabilities	(103,965)	-	-	(103,965)
Net assets March 31, 2011	<u>295,399</u>	<u>330,047</u>	<u>258,190</u>	<u>883,636</u>